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Background: To investigate the correlation between CYP3A4/5 activity and clarithromycin metabolism, and between CYP3A activity and CYP3A
genotype.
Methods: This is an open-label, prospective pharmacokinetic study evaluating CYP3A activity using The Erythromycin Breath Test. Eight blood
samples were collected within 12 h after clarithromycin 500 mg was administered orally. The clarithromycin concentrations were measured by
liquid chromatography–tandem mass spectrometry. AUC, Tmax and Cmax were calculated. Selected Single Nucleotide polymorphisms in
CYP3A4/5 genes were assessed by PCR and single base extension.
Results: Twenty-one chronically infected patients were included. An 8-fold variation in the CYP3A4 activity, 10-fold variation in AUC for
clarithromycin (median 881 μg/mL × min), and a 16-fold variation in Cmax for clarithromycin (median 3.4 μg/mL) were found. A linear
correlation between the CYP3A4-activity and clarithromycin metabolism was demonstrated (P b 0.05).
Conclusion: The large variation in the clarithromycin pharmacokinetics in cystic fibrosis patients may cause treatment failure. The Erythromycin
Breath Test could be valuable in identifying cystic fibrosis patients in risk of treatment failure/drug toxicity.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: SNPs; ERMBT; AUC; Cytochrome P450☆ Part of this work was presented at the 21st ECCMID/27th ICC,Milano, Italien
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differences in CYP3A4 activity in patients with Cystic Fibrosis (CF)— a reason of
treatment failure?”
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Chronic pulmonary infections increase the morbidity and
mortality in patients with cystic fibrosis (CF). The introduction
of antibiotic treatment with regular intervals has improved their
survival significantly and children born today with CF have
a predicted median survival of close to 40 years in USA [1]
and more than 50 years in the Copenhagen CF Centre at
Rigshospitalet. At the Copenhagen CF Centre, patients with
chronic infections are treated for 14 days every third monthby Elsevier B.V. All rights reserved.
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regimen has been shown to increase survival significantly [2].
Between the IV treatments, patients are given oral and/or inhaled
antibiotics according to the antimicrobial susceptibility testing [3].
It is therefore important that the concentration of the antibiotic used
reaches therapeutic levels to avoid development of resistance and
treatment failure.
Numerous antimicrobials are either substrates or inhibitors of
the hepatic enzyme subfamily cytochrome P4503A4 (CYP3A4)
[4]. Thus, CF patients receiving concomitantly administered
antimicrobial agents are at risk of kinetic drug interactions
and subsequent adverse effects [5,6]. This leads to signifi-
cant difficulties when trying to achieve optimal treatment
dosage.
Clarithromycin (CLR) is frequently used in the treatment
of CF patients. It is extensively metabolised by CYP3A to
14-hydroxyCLR [7] and exerts inhibitory properties. Tradi-
tionally, the treatment dosage is calculated based on body
weight and renal function of the patient. Inter-individual
differences in the pharmacokinetics of administered drugs
are significant contributors to the variability of both the
treatment effect and severity of side effects [8]. It is therefore
important to have reliable methods, which may predict the
pharmacokinetics of CLR to achieve the optimal treatment
dosage.
Among the human P450 enzymes, CYP3A is the most
abundant P450 isoenzyme, and approximately 37% of all currently
used drugs are substrates for CYP3A [9]. There is a wide inter-
individual variation in the CYP3A activity (up to 40–100 folds)
[10].
Four genes (CYP3A4, CYP3A5, CYP3A7 and CYP3A43)
encoding for the CYP3A enzymes have so far been described
[11] with CYP3A4 and CYP3A5 being regarded as the most
important [12]. Several Single Nucleotide polymorphisms
(SNPs) in the CYP3A genes have been described but their
importance have yet to be clearly established [13]. Active
CYP3A5 enzyme expression has been found in only 10–30%
of Caucasians and 50–60% of African Americans [14]. In
these individuals CYP3A5 accounts for up to 50% of the
metabolism of a drug and may play a significant role in the
metabolism of specific drugs. While CYP3A7 is active only
during the foetal life stage and its expression is down-regulated
shortly after delivery, mRNA expression has been demonstrat-
ed in 11% of an adult population [12]. CYP3A43 expression is
distributed ubiquitously in the body, but with the highest
expression in the prostate gland and in the testes [11] however
only contributes to 0.1–5% of CYP3A mRNA compared to
CYP3A4 [15].
The Erythromycin Breath Test (ERMBT) uses the unique
N-demethylation of erythromycin by CYP3A, and has gained
acceptance as an in vivo assay of hepatic CYP3A activity
measurement [16], and may be used to predict blood levels of
drugs metabolised by CYP3A [17].
The objectives of this study were to investigate the relationships
between ERMBT, CYP3A genotype and CLR pharmacokinetics
with the perspective of improving the treatment with antibiotics in
a very vulnerable group of patients.2. Material and methods
2.1. Patients
Clinically stable CF-patients with a chronic pulmonary in-
fection aged≥18 years were eligible for the study. Patients were
excluded if they had allergy to CLR and erythromycin. Any
treatment with ciprofloxacin, azithromycin, voriconazole or other
pharmaceuticals that might influence CYP3A activity was
discontinued at least 14 days before ERMBT was performed.
The patients were asked not to consume grapefruit or grapefruit
juice in the same period.2.2. The Erythromycin Breath Test (ERMBT)
ERMBT was performed in each patient 1 h before adminis-
tration of CLR. The ERMBT was performed essentially as
described byWatkins et al. [17]. Patients were given 0.15 MBq of
[14C-N-methyl] erythromycin in 1 mL of ethanol (Isotope
drugstore, USA) intravenously as a bolus with 5 mL of 5%
dextrose, and breath samples were collected at 0, 3, 10, 20, 30, 40,
50, and 60 min after injection. The samples were collected by the
patients breathing into a collection tube through a 1-meter long
catheter. A solution consisting of 4 mL of hyamine hydroxide
(Canberra Packard, Groningen, The Netherlands) and ethanol 1:1
with a trace amount of thymolphthalein as an indicator was used
for the trapping of 2 mmol of CO2. The specific activity of
14C
was determined by scintillation counting (scintillator, Perkin
Elmer, USA). The ERMBT results were expressed as the cal-
culated percentage of administered 14C exhaled during the first
hour after injection assuming an endogenous production of
5 mmol CO2 per m
2 body surface area per minute [4].2.3. Clarithromycin
After the ERMBT each patient received one tablet of 500 mg
CLR (Clarithromycin Hexal 500 mg). Immediately before CLR
intake, a blood sample was taken (t = 0). Additional blood
samples were taken at 15, 45, 60, 90,120, 150 and 180 min and at
6 and 12 h respectively, in 2 mL EDTA tubes. The samples were
centrifuged and plasma was separated and stored at −80 °C.2.4. CYP3A4 genotyping
Five SNPs in CYP3A4 were assessed by PCR and direct
sequencing using primes (CYP3A4*1B; c.104-288G N A, CYP
3A4*3; c.1334T N C, CYP3A4*17; c.566T N C, CYP3A4*2;
c.664T N C and CYP3A4*18A, c.878T N C), and PCR condi-
tions as previously described by He et al. 2005 and Sata et al. 2000
[15,18]. PCR products were purified using NucleoFast96PCR
plate (Machery–Nagel), directly sequenced on the forward strand
using BigDyeTerminator V1.1, and subsequently resolved on an
ABI3130xl (Applied Biosystems, Foster City, USA). NM_017460
was used as reference sequence.
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Seven SNPs in the CYP3A5 gene were detected using a
multiplex PCR assay followed by a multiplex single base
extension (SBE) reaction. The assay includes six primer pairs
that simultaneously amplify fragments of the CYP3A5 gene.
The primer design was performed using Primer 3.0 v. 0.2 [19]
and OligoAnalyzer v. 1.0.3 (Freeware; TeemuKuulasmaa,
Finland). RP-HPLC purified primers and probes were pur-
chased from DNA-technology A/S (Arhus, Denmark). Table 1
shows the primer sequences.
The multiplex PCR was amplified in a 25 μL reaction
containing 1 μL template DNA, 1× buffer (Amplitaq gold
buffer, Applied Biosystems), 5.5 mM MgCl2, 160 μM of each
dNTP, 0.04 to 0.32 μM of each primer (Table 1) and 1 Unit
Amplitaq gold DNA polymerase (Applied Biosystems). The
amplification was done in a GeneAmp® PCR System 9700
(Applied Biosystems) with the following programme: Initial
denaturation at 94 °C for 10 min followed by 30 cycles with
94 °C for 30 s, 60 °C for 30 s and 72 °C for 60 s. Final
extension at 72 °C for 10 min.2.6. Single base extension (SBE)
A multiplex SBE reaction was developed in order to
simultaneously detect the seven investigated SNPs. SBE primers
were designed using the programme OligoAnalyzer v. 1.0.3
(Freeware; TeemuKuulasmaa, Finland). The lengths of the
template specific parts of the primers were between 20 and
25 bps. In order to distinguish between the signals from the SBE
primers, the lengths were adjusted by the addition of pieces of
‘neutral’ sequences at the 5′-end of the primers (Table 2). These
sequences did not match any human sequence in the NCBI
database [20]. The purification of the PCR products, mini-
sequencing and subsequent purification of the minisequencing
reactionwere carried out in accordance to the SNaPshot protocol of
the manufacturer (Applied Biosystems). One microlitre of the
purified SBE reaction was analysed on an AB Prism 3130 Genetic
Analyser with a 36 cm capillary array, POP-4 polymer and 10 s at
3000 V injections. GeneScan-120 LIZ™ was used as internal size
standard. The data were analysed using GeneScan Analysis
software v. 3.7 (Applied Biosystems). All samples were tested in
duplicates.Table 1
Sequences of the primer sets used for CYP3A5 genotyping.
SNP Forward primer (5′-3′) Reverse pr
CYP3A5*3 TTATGGAGAGTGGCATAGGAG AGTTGTA




CYP3A5*9 TGTCTGATCTGGAGCTCGCA TCCCTTC2.7. CLR and 14-hydroxyCLR concentration measurement
Plasma-concentrations of CLR and 14-hydroxyCLR were
determined in the Laboratory for Clinical Toxicology and Drugs
Analysis of the Department of Hospital and Clinical Pharmacy at
the University Medical Center in Groningen using a validated
liquid chromatography–tandem mass spectrometry (LC–MS/MS)
[21]. CLR and 14-hydroxyCLR were measured by protein
precipitation, followed by LC with tandem mass detection. Of
each plasma sample 10 μL was mixed with 750 μL precipitation
reagent (methanol and acetonitrile 4:21 v/v) containing the
internal standard and were vortexed for 1 min, stored at −20 °C
for about 30 min to promote protein precipitation and thereafter
centrifuged at 11,000 xg for 5 min. From the clear upper layer
5 μL was injected on a 50 mm × 2.1 mm C18, 5-μm analytic
column (HyPurity Aquastar, Interscience Breda, The Netherlands)
for chromatographic separation. The column temperature was set
at 20 °C. The mobile phase had a flow of 0.3 mL/min and
consisted of an aqueous buffer (containing ammonium acetate
10 g/L, acetic acid 35 mg/L and trifluoroacetic anhydride 2 mL/L
of water), water and acetonitrile. The detector was operating in
electrospray positive ionization mode and performed selected
reaction monitoring (SRM) as scanning mode. The mass
parameters of m/z 748.5–590.2 (collision energy 18 eV) and m/z
764.4–606.2 (collision energy 20 eV) were measured with scan
width of 0.5 m/z for CLR and 14-hydroxyCLR. The ion source
spray voltage was set at 3500 V, the sheath and auxiliary gas
pressure at 35 Arbitrary Units (AU) and 5 AU, respectively and
the capillary temperature at 350 °C. The recoveries ranged from
100.1% to 116.9%, depending on the concentration. The accuracy
was between 94.6% and 100.2% for CLR and between 90.5 and
105.0% for 14-hydroxyCLR, depending on the concentration
level. The intra- and interassay coefficients of variation were less
than 7.7% over the ranges of 0.1 to 10 mg/L for both CLR and
14-hydroxyCLR. The lower limit of quantitation was 0.1 mg/L for
both CLR and 14-hydroxyCLR. CLR-containing samples were
stable (b10% loss) for at least 12 months at −20 °C.2.8. Pharmacokinetics analysis
Pharmacokinetic parameters (Cmax, Tmax and AUC) were
determined by the use of GraphPad Prism 4. AUCwas calculated








Neutral sequences and the target specific sequences used for the single base extension assay.
SNP Neutral sequence (5′-3′) Target specific sequence (5′-3′) μM Primer size (bp)
CYP3A5*3 ACAA GGTCCAAACAGGGAAGAGATA 0.15 25
CYP3A5*4 GTCTGACAA TGCTCTCCACAAAGGGGTCT 0.06 29
CYP3A5*5 AAAGTCTGACAA CAGCGGAAAACTCAAGGAGG 0.15 32
CYP3A5*6 AAAGTCTGACAA CTAAGAAACCAAATTTTAGGAACTT 0.1 37
CYP3A5*7 CACGTCGTGAAAGTCTGACAA TTTCCTTCCAGGCACCACCT 0.04 41
CYP3A5*8 CACGTCGTGAAAGTCTGACAA GTCTCTTAAAAAGTCCATGTGTAC 0.04 45
CYP3A5*9 TGCCACGTCGTGAAAGTCTGACAA CAGAAACTGCAAAAGGAGATTGAT 0.04 48
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The study was approved by the Ethics Committee of
Copenhagen (J.no (KF (01) 261286)).Written informed consents
were obtained from all patients.
3. Results
3.1. Patients
Twenty-one CF patients (19 males and 3 females) were
included in the study from February 2006 to April 2010.
The median (range) age of the patients was 33 years (21–
53 years). Sixteen patients were chronically infected with
Pseudomonas aeruginosa and one with P. aeruginosa and
Stenotrophomonas maltophilia. Two patients were chron-
ically infected with Achromobacter xylosoxidans and two
with Burkholderia cepacia complex. The lung function
was evaluated in each patient by FEV1% median (range)
at 67 (30–96). Further demographic data are shown in
Table 3.Table 3
Demographic data from the 21 CF patients included in the study.





Other than 2 2
Diabetes
Yes (no) 7 (14)
FEV1% of predicted median (range) 65 (30 to 96)
Chronic infection
P. aeruginosa 16
P. aeruginosa and S. maltophilia 1
A. xylosoxidans 2
B. cepacia complex 2
Median age (range) 34 (21 to 53)
Gender, male (female) 18 (3)
Carbamid (mmol/L) median (range) 7.2 (4.1 to 12.1)
Creatinine (μmol/L) median (range) 75.5 (55 to 126)
BMI (kg/m2) median (range) 22.4 (16.3 to 27.1)
ALAT (U/L) median (range) 31 (13 to 211)
CRP (mg/L) median (range) 5 (0 to 17)
Demographic data of the patients included in the study.3.2. Pharmacokinetics of CLR
A 10-fold variation in AUC for CLR, median (range)
881 μg/mL × min (274–2831) and a 12-fold variation in
AUC for 14-hydroxyCLR median (range) 366 μg/mL × min
(84–1041) were observed. Variation in Cmax was 16-fold for
CLR median (range) 3.4 μg/mL (0.5–7.8) and 11-fold for
14-hydroxyCLR median (range) 0.9 μg/mL (0.2–2.2). The
means are shown in Table 4. The median (range) Tmax was
96 min (34–360) and a median (range) T ½ at 437 min
(321–2575 min) for CLR and a median (range) Tmax at
123 min (45–360 min), and a median (range) T ½ at 768.5 min
(415–1848) for the 14-hydroxyCLR. The ratio between the CLR
and its active metabolite 14-hydroxyCLR showed a large
variability with a median (range) ratio of 2.4 (1.2 to 8.9). Two
patients (numbers 1 and 7) had very high ratio at 8.9 and 8.7
respectively, which is almost 4 times above the median.
3.3. ERMBT
A large variation in the CYP3A activity expressed as
(ERMBT %14C/h) values was found with an 8-fold variation
and a median (range) of 0.8 (0.25–2.0). One patient (number
20) had a very high activity at 2%14C/h, 2.5 fold higher
compared to the median. Two patients (numbers 1 and 7) had
very low activities (0.25 and 0.4%14C/h, respectively), which
are 3 and 2 folds below the median. Neither patient number 1, 7
or 20 had a different genotype compared to the rest of the
population that could explain this difference, they were all
homozygotes for CYP3A4*1A, and CYP3A5*3.
3.4. Correlation between the ERMBT and CLR metabolism
A significant correlation between the metabolism of CLR,
expressed as the AUC CLR/AUC 14-hydroxyCLR ratio and the
CYP3A4 activity expressed as the ERMBT was observed
(Fig. 1), (P = 0.0092; r2 = 0.31). No correlation between the
plasma-concentration of CLR and hydroxyCLR and the
ERMBT was found.
3.5. CYP3A4/5 SNPs
No differences in CYP3A4 genotypes between patients were
found. Two patients (patient numbers 4 and 9) were found to
have one copy of a functional CYP3A5 gene (CYP3A5*1) (9.5%
of the population) and none were homozygote CYP3A5*1. There
Table 4
Pharmacokinetics of CLR and its active metabolite 14-hydroxy-CLR is shown.
AUC (μg/mL × min) (mean+/−SD) Cmax (μg/mL) (mean+/−SD) Tmax (min) (mean+/−SD) T ½ (min) (mean+/−SD)
Clarithromycin 1082+/−615 3.6+/−2 124+/−85 582+/−463
14-hydroxy-CLR 425+/−233 1.0+/−0.5 135+/−87 845+/−357
The pharmacokinetics of CLR and its active metabolite 14-hydroxy-CLR.
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CYP3A4 activity. The two patients with one copy of the
functional CYP3A5 gene (CYP3A5*1) did not show higher
CYP3A activity (0.98 and 0.83, respectively) (ERMBT%14C/h),
or difference in the (AUC CLR/AUC 14-hydroxyCLR) ratio
(2.23 and 1.75, respectively).4. Discussion
We observed a large variability in the pharmacokinetic
parameters of CLR and its active metabolite in the 21 CF patients
after administration of a single dose of 500 mg CLR. AUC varied
10-fold and Cmax 16-fold.
Several factors can influence whether therapeutic drug
concentration is reached, and it is well known that different
pharmacokinetic parameters are altered in CF patients [22] making
antibiotic dosage difficult. Gilljam et al. found sub-therapeutically
serum level of CLR in ⅔ of the patients 2 h after oral intake [23]
stressing the need of therapeutic drug monitoring. This corre-
sponds to our results, which suggests that some patients might be at
risk of toxic side effects and others of treatment failure.
We found an 8-fold variation in the CYP3A activity, 2 patients
with very low values (numbers 1 and 7), and 1 patient (number 20)
with very high values compared to the median. Giving the former
two patients with low CYP activity a therapeutic CLR dose mayFig. 1. Correlation between the metabolism of CLR, expressed as the AUC
CLR/AUC 14-hydroxy-CLR ratio, and the CYP3A4 activity expressed as the
ERMBT (P = 0.0092; r2 = 0.31). Each dot represents a patient.lead to toxic high serum-concentrations while the same dose may
result in therapeutic failure in patient number 20 with a high CYP
activity.
We therefore investigated if there was a correlation between the
ERMBT and the metabolism of CLR expressed as the ratio
between the AUCCLR/AUC 14-hydroxyCLR since the macrolide
antibiotic clarithromycin is extensively metabolised by CYP3A to
14-hydroxyCLR [7]. The ratio of clarithromycin to14-
hydroxyCLR (e.g. the ratio of parent compound to metabolite
area under the curve(s)) may therefore relate to enzyme activity. A
high ratio corresponding to low enzyme activity, and the
opposite with a low ratio. We found a significant correlation
between the CLR/metabolite ratio and the ERMBT value. This
indicates that patients with high ERMBT values metabolise
CLR at a greater rate compared to patients with low ERMBT
values. The ERMBT is a validated method of assessing the
CYP3A activity in vivo although its capability of predicting total
drug clearance is less clear [4,17]. Schmidt et al. found that the
ERMBT could be used to predict cyclosporine and tacrolimus
nephrotoxicity after liver transplantation [16], and patients with
low ERMBT values are more likely to have poor drug clearance
[4]. As the ERMBT is easy to perform and fast to analyse, it
would be interesting to see if the use of this test to individualize
treatment could result in optimized treatment with subsequent
better results.
One of the limitations in the study is that the ERMBT is
performed by IV administered erythromycin, and CLR is given
orally thus, the results may be influenced by the difference in
bioavailability. The bioavailability of 250 mg CLR is described to
be 52–55% in healthy volunteers [24]. However, this may be
different in CF patients due to pancreatic insufficiency, bile acid
malabsorption and gastric acid hypersecretion making it difficult
to estimate bioavailability and the role of the intestine in these
patients. Beringer et al. found no difference of the bioavailability
of azithromycin in CF patients compared to healthy controls [25]
but Han et al. found that CF patients had lower bioavailability of
voriconazole compared to controls [26]. It is therefore difficult to
predict the contributing role of the intestines in the metabolism of
CLR, which would be interesting to investigate.We are well aware
that our patient group is small, and larger studies will be required
to confirm the conclusions of the study. Furthermore, we were not
able to investigate the potential influence of renal clearance of
CLR, which might have an influence on the results as well, and in
future studies we would like to take this into account. More males
than females were included in our study, due to the fact that we
were not able to recruit more females among our adult CF patients.
This is only partly due to the general gender distribution in adult
CF populations since males have better prognosis than females
[27].
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the metabolism of CLR in CF patients. Our results indicate
that CF patients could benefit from a pre-treatment ERMBT
in order to identify individual patients in which dose titration
might be useful in order to avoid toxicity or therapeutic
failure.
To investigate if the activity correlated with different CYP3A
genotypes we assessed five different SNPs in the CYP3A4 gene
(CYP3A4*1B, CYP3A4*3, CYP3A4*17, CYP3A4*2 and CYP3
A4*18A). The CYP3A4*1B genotype is very common among
African Americans (35–67%), present in 2–9.6% of Caucasians
but is totally absent in the Asian population [28]. The effect of
this SNP is controversial and has been associated with high
enzyme activity in some studies and with low enzyme activity in
others [29]. In Caucasians, the prevalence ofCYP3A4*2 has been
reported to be 2.7%, the prevalence ofCYP3A4*3 to be 0.47–4%,
the prevalence of CYP3A4*17 to be 2.1% and the prevalence of
CYP3A4*18A to be 0 [28]. All the patients in this study were
genotyped to be homozygote for the wild type CYP3A4 allele
(homozygote for CYP3A4*1A). The assessed CYP3A4 SNP's all
display a low minor allele frequency in Caucasians, and thus, our
results are not unexpected, but the low number of tested patients
do not allow a firm conclusion. The direct sequencing approach
did not reveal other variations. There was no obvious genotype–
phenotype correlation.
We genotyped 7 SNPs in the CYP3A5 gene and these are
shown in Table 2. CYP3A5*3, CYP3A5*6 and CYP3A5*7 are
associated with decreased activity, where the latter two are
only found in an African, or African American population [29].
CYP3A5*3 is very common in Caucasians with 83% being
CYP3A5*3 homozygote and approx. 17% being heterozygote
[30]. Expressing of the CYP3A5 enzyme has been associated
with a greater clearance of cyclosporine and tacrolimus [31] in
patients.
All but 2 (9.5%) of our patients were genotyped as
homozygotes for the CYP3A5*3 allele (CYP3A5*1/*3). There-
fore the majority of the patients, in accordance with the literature,
have no functional CYP3A5 gene. Due to the homogeneity of our
cohort, i.e. the high prevalence of the CYP3A5*3 polymorphism,
we were not able to detect a genotype–phenotype correlation. A
larger cohort of CF patients will be required to evaluate this
correlation.
The assessed CYP3A polymorphisms could not explain
the large variability in the pharmacokinetics of CLR, and
other factors e.g. the possible differences of the bio-
availability in CF patients, or other CYP enzymes might
explain some of the variability, but this would need further
investigations.
In conclusion, we found a high degree of variation in the
pharmacokinetic parameters of CLR and its metabolite. This
may lead to treatment failure or adverse drug effects. There
was a significant correlation between the metabolism of CLR
and the ERMBT. Further studies are therefore needed to
evaluate the value of the ERMBT as a method to individualize
the dosage of CLR or other drugs in CF and other patient
groups as a supplement to conventional parameters like body
weight or renal function.Acknowledgements
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